In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis.

ABSTRACT:

Importance

Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown.

Objective

To investigate CB1R availability in first-episode psychosis (FEP) without the confounds of illness chronicity or the use of illicit substances or antipsychotics.

Design, setting, and participants

This cross-sectional, case-control study of 2 independent samples included participants receiving psychiatric early intervention services at 2 independent centers in Turku, Finland (study 1) and London, United Kingdom (study 2). Study 1 consisted of 18 volunteers, including 7 pa

SUBMITTER: Borgan F 

PROVIDER: S-EPMC6613300 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature